Biohaven Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-846.42	-408.17	-570.28	-213.8	-118.67
Depreciation & Amortization	7.86	6.91	1.39	1.39	0.07
Loss (Gain) From Sale of Investments	-	-	10	-5.26	4.16
Stock-Based Compensation	71.96	28.79	193.56	65.64	29.5
Other Operating Activities	167.34	16.13	96.25	4.52	-
Change in Accounts Payable	0.71	4.87	5.93	1.03	0.22
Change in Other Net Operating Assets	16.1	19.74	-34.53	0.64	8.76
Operating Cash Flow	-582.45	-331.73	-297.69	-145.84	-75.96
Capital Expenditures	-4.05	-3.05	-6.07	-0.94	-2.7
Cash Acquisitions	0.39	-	-35	1.88	-
Investment in Securities	-241.32	132.88	-263.72	-	-
Investing Cash Flow	-244.97	129.83	-304.79	0.94	-2.7
Issuance of Common Stock	677.67	247.92	284.26	0.4	-
Other Financing Activities	0.11	-36.01	483.34	138.05	152.24
Financing Cash Flow	677.77	211.91	767.6	138.45	152.24
Foreign Exchange Rate Adjustments	0.08	-0.5	0.43	-	-
Net Cash Flow	-149.58	9.52	165.55	-6.45	73.59
Free Cash Flow	-586.5	-334.77	-303.76	-146.78	-78.65
Free Cash Flow Per Share	-6.43	-4.70	-6.79	-3.73	-2.00
Cash Interest Paid	0.13	-	-	0.11	-
Cash Income Tax Paid	-10.44	-33.3	38.17	16.59	2.76
Levered Free Cash Flow	-364.16	-213.77	-223.44	-69.94	-
Unlevered Free Cash Flow	-364.16	-213.77	-223.44	-69.94	-
Change in Net Working Capital	-106.46	-26.11	57.36	-0.78	-

Updated Mar 3, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q